Policy & Regulation
Pharmazz wins Indian Patent for the pharmaceutical composition of IRL-1620 to evaluate dogs with degenerative myelopathy, similar to human ALS
12 January 2018 -

Medicine company Pharmazz Inc reported on Thursday the receipt of the Indian Patent No. 290038 for the pharmaceutical composition of IRL-1620 (PMZ-1620).

According to the company, PMZ-1620 is a selective endothelin-B receptor agonist that is presently undergoing clinical studies in patients suffering from mild to moderate Alzheimer's disease. A phase II study, using PMZ-1620, is being conducted in patients with cerebral ischemic stroke.

Following the patent, the company has launched a study to evaluate PMZ-1620 in dogs with degenerative myelopathy, a spinal cord disease of dogs, progressing from weakness to eventual paralysis. Degenerative myelopathy has pathological, genetic and clinical features similar to human amyotrophic lateral sclerosis (ALS).

The Institute for Healthcare Innovation, College of Veterinary Medicine and Chicago College of Pharmacy at Midwestern University have announced a partnership to evaluate PMZ-1620 in dogs with degenerative myelopathy.

Pharmazz Inc, which has exclusive rights to PMZ-1620 from Midwestern University, plans to initiate studies in patients with amyotrophic lateral sclerosis if the results of this study in dogs with degenerative myelopathy are positive.



Related Headlines